Delivery Order SPE2DB20D3103-SPE2DB25FQ0P9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for dapagliflozin 10 mg tablets in a quantity of 30-unit packages, with a ceiling value of $5,581.69. This contract, awarded on August 7, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and carries no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $38,360.32 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 5 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, competitively awarded delivery order was issued with no set-aside designation and represents performance at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $1,070.46 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packages) with an ultimate completion date of August 15, 2025. This competitively awarded contract, issued on August 14, 2025, utilizes a firm fixed price structure with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count) with a ceiling value of $5,275.63. This competitive, non-set-aside delivery order represents a firm fixed price transaction with an ultimate completion date of July 29, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a $5,346.26 delivery order to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order, indicating it is issued under a larger indefinite delivery contract (IDC) vehicle. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $1,036.29. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 tablets per package. This is a firm fixed-price delivery order with a ceiling value of $1,315.41, with an ultimate completion date of July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, valued at $29,475.49 under a firm fixed-price contract. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The award carries no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ0P9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 5 mg tablets (30-count) on August 28, 2025, with a ceiling value of $1,296.48 and an ultimate completion date of August 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for military and veteran healthcare systems. The delivery order falls under AmerisourceBergen's comprehensive $999,999,999 IDC vehicle valued through December 2026, which enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs. Dapagliflozin, a diabetes management medication, represents a typical commodity within the company's extensive portfolio of therapeutic products delivered to the Defense Health Agency and other government healthcare entities. This transaction exemplifies the routine pharmaceutical supply chain operations conducted through DLA's established vendor relationships to support ongoing defense medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/28/25 |